Linked Life Data

17408115

Source:http://linkedlifedata.com/resource/pubmed/id/17408115

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-4-5
pubmed:abstractText
There is increasing evidence that therapeutic agents for raising HDL would be a useful addition to the current treatment approach for preventing coronary heart disease (CHD), especially considering the fact that therapies for lowering LDLs are not fully adequate for preventing CHD. The recent unraveling of some of the complexities of HDL metabolism has led to the identification of new key proteins involved in HDL metabolism, thus giving new hope and ideas for drug targets. This review focuses on apolipoprotein AI mimetic peptides, which are currently being explored as therapeutic agents for a new treatment strategy known as acute HDL therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1472-4472
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
201-12
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis.
pubmed:affiliation
National Institutes of Health, Lipoprotein Metabolism Section, Vascular Medicine Branch, National Heart, Lung and Blood Institute, Bldg 10, Room 7N-115, 10 Center Drive, Bethesda, MD 20892-1508, USA.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't